Trial Profile
CAR-T Therapy for Central Nervous System B-cell Acute Lymphocytic Leukemia
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 16 Jun 2019
Price :
$35
*
At a glance
- Drugs Chimeric-antigen-receptor-T-cell-therapeutics-Shanghai-Unicar-Therapy-Bio-medicine-Technology (Primary)
- Indications Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Therapeutic Use
- Sponsors Shanghai Unicar-Therapy Bio-medicine Technology
- 31 Aug 2018 Biomarkers information updated
- 21 May 2018 Planned End Date changed from 18 Feb 2019 to 18 Feb 2020.
- 21 May 2018 Planned primary completion date changed from 1 Aug 2018 to 1 Aug 2019.